论文部分内容阅读
目的观察辛伐他汀联合依折麦布对冠心病并心力衰竭患者的疗效。方法冠心病并心力衰竭患者68例随机分为观察组和对照组各38例,观察组基础治疗+辛伐他汀(20mg,1次/d,晚餐时服)+依折麦布(10mg,1次/d,晚餐时服);对照组:基础治疗+辛伐他汀(20mg,1次/d,晚餐时服),治疗前及治疗后3个月时测定血清TC、LDL2C和CRP水平,采用超声心动图测量左室射血分数(LVEF)。结果治疗3个月后,两组TC、LDL2C和CRP均较治疗前改善,差异有统计学意义(P<0.05),治疗后观察组较对照组TC、LDL2C和CRP改善更显著,差异有统计学意义(P<0.05)。两组LVEF均较治疗前明显改善,差异有统计学意义(P<0.05),治疗后观察组较对照组,LVEF差异无统计学意义(P>0.05)。联合组较对照组不增加不良反应。结论冠心病心力衰竭患者在基础治疗基础上辛伐他汀联合依折麦布,较单用辛伐他汀可以进一步改善血脂和心功能。
Objective To observe the effect of simvastatin combined with ezetimibe on patients with coronary heart disease and heart failure. Methods Sixty-eight patients with coronary heart disease and heart failure were randomly divided into observation group (38 cases) and control group (38 cases). The observation group was treated with simvastatin (20 mg once daily, The control group: basic treatment + simvastatin (20mg, 1 times / d, dinner time service), before treatment and 3 months after treatment, serum TC, LDL2C and CRP levels were measured using Echocardiography measured left ventricular ejection fraction (LVEF). Results After treatment for 3 months, TC, LDL2C and CRP in both groups improved compared with those before treatment, with significant difference (P <0.05). After treatment, TC, LDL2C and CRP in observation group improved more significantly than those in control group Significance (P <0.05). LVEF in both groups was significantly improved compared with that before treatment (P <0.05). There was no significant difference in LVEF between the observation group and the control group after treatment (P> 0.05). Combination group than the control group did not increase adverse reactions. Conclusions Simvastatin combined with ezetimibe based on basic treatment can further improve blood lipid and cardiac function in patients with heart failure of coronary heart disease compared with single use of simvastatin.